Akmal M. Asrorov

Dr. Akmal M. Asrorov

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2023 in Drug Development Research
Verified
Journal Article
Closed access
AAAkmal M. Asrorov
Akmal M. Asrorov
Muzaffar Bakhadirovich KayumovMuzaffar Bakhadirovich Kayumov
Muzaffar Bakhadirovich Kayumov
NMNurkhodja Mukhamedov
Nurkhodja Mukhamedov
AYAnsor Yashinov
Ansor Yashinov
ZMZiyoda Mirakhmetova
Ziyoda Mirakhmetova
SMSharafitdin Mirzaakhmedov
Sharafitdin Mirzaakhmedov

28 March 2024 in Medicine in Drug Discovery
Verified
Journal Article
Open access
AAAkmal M. Asrorov
Akmal M. Asrorov
NMNurkhodja Mukhamedov
Nurkhodja Mukhamedov
Muzaffar Bakhadirovich KayumovMuzaffar Bakhadirovich Kayumov
Muzaffar Bakhadirovich Kayumov
AYAnsor Sh. Yashinov
Ansor Sh. Yashinov
AWAhmidin Wali
Ahmidin Wali
YHYongzhuo Huang
Yongzhuo Huang

4 May 2021 in Nanoscale
Verified
Journal Article
Closed access
PDF file
AAAkmal M. Asrorov
Akmal M. Asrorov
ZGZeyun Gu
Zeyun Gu
FLFeng Li
Feng Li
LLLingyun Liu
Lingyun Liu
YHYongzhuo Huang
Yongzhuo Huang
Cancer remains a significant challenge despite the progress in developing different therapeutic approaches. Nanomedicine has been explored as a promising novel cancer therapy. Recently, biomimetic camouflage strategies have been investigated to change the bio-fate of therapeutics and target cancer cells while reducing the unwanted exposure on normal tissues. Endogenous components (e.g., proteins, polysaccharides, and cell membranes) have been used to develop anticancer drug delivery systems. These biomimetic systems can overcome biological barriers and enhance tumor cell–specific uptake. The tumor-targeting mechanisms include ligand–receptor interactions and stimuli-responsive (e.g., pH-sensitive and light-sensitive) delivery. Drug delivery carriers composed of endogenous components represent a promising approach for improving cancer treatment efficacy. In this paper, different biomimetic drug delivery strategies for cancer treatment are reviewed with a focus on the discussion of their advantages and potential applications.

10 November 2020 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
BTBin Tu
Bin Tu
YHYang He
Yang He
BCBinfan Chen
Binfan Chen
YWYonghui Wang
Yonghui Wang
YGYanrong Gao
Yanrong Gao
YHYongzhuo Huang
Yongzhuo Huang
The tumor microenvironment (TME) and its major component tumor-associated macrophages (TAM) play a pivotal role in the development of non-small cell lung cancer (NSCLC). An epigenetic drug-based combinatory therapeutic strategy was proposed and a deformable liposome system (D-Lipo) was developed for vorinostat and simvastatin codelivery for remodeling the TME. The application of deformable liposomes in systemic cancer drug delivery has been underexplored and its potential in cancer therapy is largely unknown. This work revealed that D-Lipo exhibited an enhanced intratumor infiltration ability. The proposed therapeutic strategy was characterized by a chemo-free regimen and TME remodeling function. D-Lipo efficiently inhibited the growth of the xenografted lung tumor. The anti-tumor mechanisms involved the repolarization of TAM from the M2 to M1 phenotype, anti-angiogenesis, and the consequent TME remodeling. As a result, the amounts of the anti-tumor M1 macrophages and the cytotoxic CD8+ T cells increased, while the amounts of the pro-tumor M2 macrophages and regulatory T cells (Tregs) reduced. It provides a promising avenue for epigenetic drug-based combination therapy for treating solid tumors.

17 May 2023 in Drug Development Research
Verified
Journal Article
Closed access
AAAkmal M. Asrorov
Akmal M. Asrorov
HWHuiyuan Wang
Huiyuan Wang
MZMeng Zhang
Meng Zhang
YWYonghui Wang
Yonghui Wang
YHYang He
Yang He
YHYongzhuo Huang
Yongzhuo Huang

31 December 2021 in Nanoscale
Verified
Journal Article
Closed access
PDF file
YWYonghui Wang
Yonghui Wang
BCBinfan Chen
Binfan Chen
ZHZhidi He
Zhidi He
BTBin Tu
Bin Tu
PZPengfei Zhao
Pengfei Zhao
YHYongzhuo Huang
Yongzhuo Huang
In this “two-birds-one stone” strategy using celastrol NP-containing M1Φ, M1Φ serves as not only a cell therapeutic agent but also a carrier for celastrol NPs that, in turn, facilitate M1 polarization. The exocytosed NPs can also kill tumor cells.